Umbilical cord blood bilirubins, gestational age, and maternal race predict neonatal hyperbilirubinemia
Adrian Castillo, Tristan R Grogan, Grace H Wegrzyn, Karrie V Ly, Valencia P Walker, Kara L Calkins, Adrian Castillo, Tristan R Grogan, Grace H Wegrzyn, Karrie V Ly, Valencia P Walker, Kara L Calkins
Abstract
Objective: No validated biomarker at birth exists to predict which newborns will develop severe hyperbilirubinemia. This study's primary aim was to build and validate a prediction model for severe hyperbilirubinemia using umbilical cord blood bilirubins (CBB) and risk factors at birth in neonates at risk for maternal-fetal blood group incompatibility. This study's secondary aim was to compare the accuracy of CBB to the direct antigen titer.
Methods: Inclusion criteria for this prospective cohort study included: ≥35 weeks gestational age, mother with blood type O and/or Rh negative or positive antibody screen, and <24 hours of age. The primary outcome was severe hyperbilirubinemia, defined as phototherapy during the initial hospital stay. Secondary outcomes were a total serum bilirubin concentration >95th and >75th percentile during the initial hospital stay. The predictive performance and accuracy of the two tests (CBB and direct antigen titer) for each outcome was assessed using area under a receiver-operating characteristic curve (AUC), sensitivity, and specificity.
Results: When compared to neonates who did not receive phototherapy (n = 463), neonates who received phototherapy (n = 36) had a greater mean CBB ± standard deviation (2.5 ± 0.7 vs. 1.6 ± 0.4 mg/dL, p<0.001). For every 0.3 mg/dL increase in CBB, a neonate was 3.20 (95% confidence interval, 2.31-4.45), 2.10 (1.63-2.70), and 3.12 (2.44-3.99) times more likely to receive phototherapy or have a total serum bilirubin concentration >95th and >75th percentile, respectively. The AUC ± standard error (95% confidence interval) for CBB for phototherapy and a total serum bilirubin concentration >95th and >75th percentile was 0.89 ± 0.03 (0.82-0.95), 0.81 ± 0.04 (0.73-0.90), and 0.84 ± 0.02 (0.80-0.89), respectively. However, the AUC for gestational age and maternal Asian race for these outcomes was only 0.55 ± 0.05 (0.45-0.66), 0.66 ± 0.05 (0.56-0.76), and 0.57 ± 0.04 (0.05-0.64), respectively. When the CBB was combined with gestational age and maternal Asian race, the AUC for a total serum bilirubin concentration >95th percentile improved to 0.87 ± 0.03 (0.81-0.92) (p = 0.034 vs. the model with CBB only and p<0.001 vs. the model with clinical risk factors only). In a sub-group of subjects (n = 189), the AUC for the direct antigen titer for phototherapy was 0.64 ± 0.06 (0.52-0.77) with a 52% sensitivity and 77% specificity. In contrast, a CBB cut-point of 1.85 mg/dL was 92% sensitive and 70% specific for phototherapy with an AUC of 0.87 ± 0.04 (0.80-0.95).
Conclusion: CBB, in combination with gestational age and maternal race, may be a useful, non-invasive test to predict shortly after birth which neonates will develop severe hyperbilirubinemia.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Bhutani VK, Johnson L. Synopsis report from the pilot USA Kernicterus Registry. J Perinatol. 2009;29 Suppl 1:S4–7.
- Bhutani VK, Stark AR, Lazzeroni LC, Poland R, Gourley GR, Kazmierczak S, et al. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. J Pediatr. 2013;162(3):477–82 e1. doi:
- Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.
- Lee HC, Bardach NS, Maselli JH, Gonzales R. Emergency department visits in the neonatal period in the United States. Pediatr Emerg Care. 2014;30(5):315–8. doi:
- Bhutani VK, Meng NF, Knauer Y, Danielsen BH, Wong RJ, Stevenson DK, et al. Extreme hyperbilirubinemia and rescue exchange transfusion in California from 2007 to 2012. J Perinatol. 2016;36(10):853–7. doi:
- Risemberg HM, Mazzi E, MacDonald MG, Peralta M, Heldrich F. Correlation of cord bilirubin levels with hyperbilirubinaemia in ABO incompatibility. Archives of disease in childhood. 1977;52(3):219–22.
- Bernstein RB, Novy MJ, Piasecki GJ, Lester R, Jackson BT. Bilirubin metabolism in the fetus. The Journal of clinical investigation. 1969;48(9):1678–88. doi:
- Bernaldo AJ, Segre CA. Bilirubin dosage in cord blood: could it predict neonatal hyperbilirubinemia? Sao Paulo medical journal = Revista paulista de medicina. 2004;122(3):99–103.
- Calkins K, Roy D, Molchan L, Bradley L, Grogan T, Elashoff D, et al. Predictive value of cord blood bilirubin for hyperbilirubinemia in neonates at risk for maternal-fetal blood group incompatibility and hemolytic disease of the newborn. Journal of neonatal-perinatal medicine. 2015;8(3):243–50. doi:
- Ipek IO, Bozaykut A, Cagril SC, Sezer RG. Does cord blood bilirubin level help the physician in the decision of early postnatal discharge? J Matern Fetal Neonatal Med. 2012;25(8):1375–8. doi:
- Knudsen A. Prediction of the development of neonatal jaundice by increased umbilical cord blood bilirubin. Acta paediatrica Scandinavica. 1989;78(2):217–21.
- Knupfer M, Pulzer F, Gebauer C, Robel-Tillig E, Vogtmann C. Predictive value of umbilical cord blood bilirubin for postnatal hyperbilirubinaemia. Acta Paediatr. 2005;94(5):581–7. doi:
- Peeters B, Geerts I, Van Mullem M, Micalessi I, Saegeman V, Moerman J. Post-test probability for neonatal hyperbilirubinemia based on umbilical cord blood bilirubin, direct antiglobulin test, and ABO compatibility results. Eur J Pediatr. 2016;175(5):651–7. doi:
- Rosenfeld J. Umbilical cord bilirubin levels as a predictor of subsequent hyperbilirubinemia. The Journal of family practice. 1986;23(6):556–8.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.
- R Core Team. R: A language and environment for statistical computing R Foundation for Statistical Computing, Vienna, Austria: 2014.
- IBM SPSS Statistics for Windows, version 25. IBM Corp, Armonk, NY, USA.
- Mah MP, Clark SL, Akhigbe E, Englebright J, Frye DK, Meyers JA, et al. Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening. Pediatrics. 2010;125(5):e1143–8. doi:
- Darling EK, Ramsay T, Sprague AE, Walker MC, Guttmann A. Universal bilirubin screening and health care utilization. Pediatrics. 2014;134(4):e1017–24. doi:
- Farhat R, Rajab M. Length of postnatal hospital stay in healthy newborns and re-hospitalization following early discharge. North American journal of medical sciences. 2011;3(3):146–51. doi:
- Wu XJ, Zhong DN, Xie XZ, Ye DZ, Gao ZY. UGT1A1 gene mutations and neonatal hyperbilirubinemia in Guangxi Heiyi Zhuang and Han populations. Pediatr Res. 2015;78(5):585–8. doi:
- Maruo Y, Morioka Y, Fujito H, Nakahara S, Yanagi T, Matsui K, et al. Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr. 2014;165(1):36–41 e1. doi:
- Shahid R, Graba S. Outcome and cost analysis of implementing selective Coombs testing in the newborn nursery. J Perinatol. 2012;32(12):966–9. doi:
- Dinesh D. Review of positive direct antiglobulin tests found on cord blood sampling. Journal of paediatrics and child health. 2005;41(9–10):504–7. doi:
- Brouwers HA, Overbeeke MA, van Ertbruggen I, Schaasberg W, Alsbach GP, van der Heiden C, et al. What is the best predictor of the severity of ABO-haemolytic disease of the newborn? Lancet (London, England). 1988;2(8612):641–4.
- Bhutani VK, Poland R, Meloy LD, Hegyi T, Fanaroff AA, Maisels MJ. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia. J Perinatol. 2016;36(7):533–9. doi:
- Yaseen H, Khalaf M, Rashid N, Darwich M. Does prophylactic phototherapy prevent hyperbilirubinemia in neonates with ABO incompatibility and positive Coombs' test? J Perinatol. 2005;25(9):590–4. doi:
Source: PubMed